Bacopa monnieri per Attention & Focus Difficulties
C Evidenze Evidenza limitata da studi di piccole dimensioni, ma esistono alcuni segnali positivi.Research suggests Bacopa's modulation of dopamine and acetylcholine systems may support attention and focus. Effects require 8-12 weeks of consistent use for measurable improvement.
In sintesi
Research suggests Bacopa's modulation of dopamine and acetylcholine systems may support attention and focus. Effects require 8-12 weeks of consistent use for measurable improvement.
Key Study Findings
Popolazione: ADHD patients (systematic review of supplements)
Popolazione: Healthy older adults
Popolazione: Retracted publication - invasive ductal carcinoma
Popolazione: None
Popolazione: None
Popolazione: None
Key Statistics
8
Studi
600
Partecipanti
Positive
Grado
Referenced Papers
Dosage & Usage
mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units
Dosaggi di uso comune
- general:
- 300-600 mg/day standardized to 50% bacosides
- memorysupport:
- 300 mg/day for minimum 8-12 weeks
Limite massimo: Not established; well-tolerated up to 600 mg/day in trials
Dosaggi studiati nella ricerca
| Dosaggio | Durata | Effetto | N |
|---|---|---|---|
| None | -- | Mixed | -- |
| None | -- | Positive | 1861 |
| Bacopa monnieri (Brahmi) | -- | Positive | -- |
| None | 72 weeks | Positive | -- |
| None | -- | Mixed | -- |
| None | -- | Positive | -- |
| None | -- | Positive | -- |
| None | -- | Positive | -- |
Momento migliore per l'assunzione: With meals; effects require 8-12 weeks of consistent use
Safety & Side Effects
Effetti collaterali segnalati
- ⚠ Gastrointestinal discomfort (nausea, cramping, diarrhea)
- ⚠ Dry mouth
- ⚠ Fatigue in some individuals
- ⚠ Mild sedation at higher doses
Interazioni note
- ● Thyroid medications (may increase thyroid hormone levels)
- ● Anticholinergic drugs (opposes cholinergic enhancement)
- ● Sedative medications (additive CNS depression)
- ● Calcium channel blockers (may enhance blood pressure lowering)
Livello di assunzione massimo tollerabile: Not established; well-tolerated up to 600 mg/day in trials
Consultare sempre il proprio medico prima di iniziare qualsiasi integratore.Consultate sempre il vostro medico prima di iniziare qualsiasi integratore.
Frequently Asked Questions
Does Bacopa monnieri help with Attention & Focus Difficulties?
How much Bacopa monnieri should I take for Attention & Focus Difficulties?
Are there side effects of Bacopa monnieri?
How strong is the evidence for Bacopa monnieri and Attention & Focus Difficulties?
Related Evidence
Altri ingredienti per Attention & Focus Difficulties
Bacopa monnieri per altre condizioni
References
- [1] Shatha Al Shahab et al.. Nutrients. 2025. Efficiency of Different Supplements in Alleviating Symptoms of ADHD with or Without the Use of Stimulants: A Systematic Review. doi:10.3390/nu17091482 PubMed
- [2] Xueyan Feng et al.. Front Pharmacol. 2025. The effect of plant active substances on cognitive function in healthy older adults: a systematic review and network meta-analysis of … doi:10.3389/fphar.2025.1672171 PubMed
- [3] Sohini Roy et al.. Med Oncol. 2024. Exploring the immunomodulatory potential of Brahmi (Bacopa monnieri) in the treatment of invasive ductal carcinoma. doi:10.1007/s12032-024-02365-x PubMed
- [4] John E Lewis et al.. J Clin Transl Res. 2021. The effects of twenty-one nutrients and phytonutrients on cognitive function: A narrative review. PubMed
- [5] Brittany R Block et al.. Sr Care Pharm. 2021. Online Promotion of "Brain Health" Supplements. doi:10.4140/TCP.n.2021.489 PubMed
- [6] Andrea Brioschi Guevara et al.. Alzheimers Res Ther. 2021. Protocols for cognitive enhancement. A user manual for Brain Health Services-part 5 of 6. doi:10.1186/s13195-021-00844-1 PubMed
- [7] Michelle D Nemetchek et al.. J Ethnopharmacol. 2017. The Ayurvedic plant Bacopa monnieri inhibits inflammatory pathways in the brain. doi:10.1016/j.jep.2016.07.073 PubMed
- [8] Grace M McPhee et al.. Med Hypotheses. 2016. Cognitive training and Bacopa monnieri: Evidence for a combined intervention to alleviate age associated cognitive decline. doi:10.1016/j.mehy.2016.09.002 PubMed
- [9] Ananya Sadhu et al.. Clin Drug Investig. 2014. Management of cognitive determinants in senile dementia of Alzheimer's type: therapeutic potential of a novel polyherbal drug product. doi:10.1007/s40261-014-0235-9 PubMed
- [10] P M Kidd. Altern Med Rev. 1999. A review of nutrients and botanicals in the integrative management of cognitive dysfunction. PubMed
Avvertenza FDA: Queste affermazioni non sono state valutate dalla Food and Drug Administration. I prodotti e le informazioni presenti su questo sito web non sono destinati a diagnosticare, trattare, curare o prevenire alcuna malattia. I gradi di evidenza presentati si basano sulla nostra analisi della ricerca pubblicata e sottoposta a revisione paritaria e non costituiscono consulenza medica. Consultate sempre il vostro medico prima di iniziare qualsiasi regime di integrazione.